Kadmon Hlds

Kadmon Corporation, a biopharmaceutical company, offers products and services for the treatment and management of hepatitis C. Its products include Ribasphere RibaPak (ribavirin, USP) tablets, which help to reduce pill burden while providing patients with treatment that is biologically equivalent to other ribavirin medications; INFERGEN (interferon alfacon-1) to treat chronic hepatitis C in patients 18 years of age or older with compensated liver disease; Ribasphere (ribavirin, USP) tablets and capsules, which are antiviral medications for use in combination with other drugs for the treatment of chronic hepatitis C; and KD020, a reversible tyrosine kinase inhibitor that targets EGFR, HER2, VEGFR 2/3, and Src in autosomal dominant polycystic kidney disease (PKD). The company also provides various services and programs to support patients, prescribers, and pharmacies, including patient assistance programs to provide free medication to patients with limited or no insurance coverage; temporary shipments for patients on current or recent therapy; and nurse support services. In addition, it develops medicines in oncology, infectious diseases, immunology, and neurodegenerative diseases.  The company was formerly known as Kadmon Holdings. Kadmon Corporation was incorporated in 2009 and is based in New York, New York with operations in Warrendale, Pennsylvania; and Boston, Massachusetts.

Sanofi

Sanofi completes acquisition of Kadmon

Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and 3393.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kadmon Holdings, Inc. (KDMN) Reports Q3 Loss, Tops Revenue Estimates

- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - Sanofi acquisition of Kadmon expected to close 4Q 2021 - NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021. "The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following our strategic commercial launch," said Harlan W.

Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

Bellus Health Inc

Leap Therapeutics

Find out why last month was a big one for these three drugmakers.

3 Biotech Stocks That Surged in September

NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-15 preclinical work, at the Society for Immunotherapy of Cancer's (SITC 2021) 36th Annual Meeting, taking place virtually November 10 - 14, 2021. Details of the presentations are outlined below.

Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting

Echo Global Logistics

JMP Group

NEW YORK, Sept. 30, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.

SHAREHOLDER ALERT: WeissLaw LLP Reminds CXP, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations

BioNTech SE

GlaxoSmithKline

Novo Nordisk

Pfizer

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

NEW ORLEANS, Sept. 21, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN

First Interstate BancSystem

Triple-S Management

Hill-Rom Hlds

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Triple-S Management Corporation (NYSE: GTS)  concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to GuideWell Mutual Holding Corporation for $36.00 per share in cash.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTS, HRC, JMP, KDMN, FIBK; Shareholders are Encouraged to Contact the Firm

Diversicare Healthcare Services

NEW YORK, Sept. 17, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.

SHAREHOLDER ALERT: WeissLaw LLP Reminds ECHO, KDMN, HRC, and DVCR Shareholders About Its Ongoing Investigations

NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Kadmon Holdings, Inc. ("KDMN" or the "Company") (KDMN) relating to its proposed acquisition by Sanofi.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kadmon Holdings, Inc. - KDMN

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kadmon Holdings, Inc. (NASDAQ: KDMN) and its board of directors concerning the proposed acquisition of the company by Sanofi (NASDAQ: SNY).

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.

Kadmon is one of the highest shorted tickers on NASDAQ.

Kadmon, The Big Short

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kadmon Holdings, Inc. (NASDAQ: KDMN) to Sanofi for $9.50 per share in cash is fair to Kadmon shareholders. Halper Sadeh encourages Kadmon shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Kadmon and its boa

Kadmon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kadmon Holdings, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – KDMN

The stock price of Kadmon Holdings Inc (NASDAQ: KDMN) increased 71.13% today. This is why it The post KDMN Stock: Why It Surged Today appeared first on Pulse 2.0.

KDMN Stock: Why It Surged Today

MILWAUKEE, Sept. 8, 2021 /PRNewswire/ -- Ademi LLP is investigating Kadmon (NASDAQ:KDMN), for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.

Shareholder Alert: Ademi LLP investigates whether Kadmon Holdings, Inc. has obtained a Fair Price in its transaction with Sanofi

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.

Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock

Kadmon Holdings (KDMN) stock is rising higher on Wednesday following news of a deal with Sanofi (SNY) that comes to $1.9 billion. The post KDMN Stock: 6 Things to Know About Biopharma Kadmon Holdings as Shares Skyrocket appeared first on InvestorPlace.

KDMN Stock: 6 Things to Know About Biopharma Kadmon Holdings as Shares Skyrocket

Sanofi adds another bolt-on acquisition in what is turning out to be a busy year for the French pharma titan.

Why Kadmon Holdings Stock Is Rocketing Higher Today

French drugmaker Sanofi is buying Kadmon, the U.S. biopharmaceutical company, for a total equity value of $1.9 billion.

Kadmon Stock Soars as Sanofi Buys U.S. Biotech for $1.9 Billion

Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another billion-dollar deal. Sanofi-Kadmon Deal Terms: Sanofi announced Wednesday it has agreed to acquire New York-based biopharma Kadmon Holdings, Inc. (NASDAQ: KDMN) in a $1.9 billion all-cash deal.

Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know

The stock price of Kadmon Holdings Inc (NASDAQ: KDMN) increased by over 75% pre-market. This is why it happened.

KDMN Stock: Over 75% Stock Increase Pre-Market Explanation

French pharmaceutical major Sanofi SA said Wednesday that it has entered into a definitive agreement to acquire U.S.-based biopharmaceutical company Kadmon Holdings Inc.

Sanofi to acquire U.S. biopharmaceutical group Kadmon in $1.9 billion deal

French drugmaker Sanofi SA has agreed to buy U.S. biopharmaceutical company Kadmon Holdings Inc in a $1.9 billion deal, the companies said on Wednesday.

France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 billion deal

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy PARIS, FRANCE and NEW YORK, NY / ACCESSWIRE / September 8, 2021 / Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. (NASDAQ:KDMN) a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease areas of significant unmet medical needs. The acquisition supports Sanofi's strategy to continue to grow its General Medicines core assets and will immediately add Rezurock™ (belumosudil) to its transplant portfolio.

News for Kadmon Hlds Stock (KDMN)